# Niacin Cholesterol Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/niacin-cholesterol-meta-analysis-evidence-review
Category: evidence-review
Summary: Niacin Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed 
Last reviewed: 2026-05-22
Reviewed by: Migaku Evidence Review
# Niacin Cholesterol Meta-analysis: What the Evidence Says

## Quick Answer

Niacin Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes | narrative review | 3 | 2026-02-23 | 10.1177/11795514261422310 |
| Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update | preclinical study | 4 | 2026-03-12 | 10.3390/jcm15062179 |

## What The Sources Report

- There is growing interest in examining whether lipid-lowering treatment in diabetes is associated with cardiovascular outcomes. [Abdul Wahab Roshaida (2026); evidence level 3]
- This review aims to provide a summary that will help navigate the extensive evidence base on cardiovascular outcomes trials of these agents. [Abdul Wahab Roshaida (2026); evidence level 3]
- Since its discovery over half a century ago, Lp(a) has attracted considerable interest due to its strong, genetically determined association with atherosclerotic cardiovascular disease (ASCVD), independent of traditional lipid risk factors. [Domański Igor (2026); evidence level 4]
- Elevated Lp(a) concentrations-particularly those above 50 mg/dL-have been strongly linked to an increased risk of myocardial infarction, ischemic stroke, peripheral artery disease, heart failure, and aortic valve stenosis. [Domański Igor (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For niacin cholesterol meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Abdul Wahab Roshaida (2026). Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes. DOI: 10.1177/11795514261422310. PMCID: PMC12929832. PMID: 41743491. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ https://us.sagepub.co.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12929832/
- Domański Igor (2026). Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update. DOI: 10.3390/jcm15062179. PMCID: PMC13027314. PMID: 41899103. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13027314/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.